Blog
What You Need to Know About the COSMOS-Standard for Natural & Organic Cosmetic Products
Nov 19 2019
What is the COSMOS-Standard? COSMOS (“COSMetic Organic and Natural Standard”) is a single, international standard for natural and organic cosmetic products which became effective in January of 2010. The five foremost organizations involved in organic and natural cosmetics standards came together to develop a single, harmonized standard to ensure: A level playing field Efficient operation…
Read More →
FDA Grants First-Ever Modified Risk Orders for Smokeless Tobacco Products
Nov 14 2019
FDA recently granted the first-ever modified risk orders to eight smokeless tobacco products. In a recent press release, FDA announced the authorizations are for Swedish Match USA, Inc. snus smokeless tobacco products, which are marketed and sold under the “General” brand name. The Products were Previously Authorized Under PMTA The 8 snus smokeless tobacco products…
Read More →
Best-In-Class Polymer Additive Library for Identification of Extractables
Nov 12 2019
In the biopharmaceutical industry, it’s important to identify extractables and leachables for patient safety and submissions to regulatory authorities. Impurities can originate from process components, manufacturing equipment, packaging materials, and container closure systems used in the development of a drug product. Extractable and leachables (E&L) studies detect and identify the organic and inorganic compounds that…
Read More →
Development of a Library of Plastic Additives for Identification of Extractables Poster Presentation
Nov 5 2019
Avomeen’s extractables and leachables (E&L) team are attending AAPS PharmSci360 November 3-6, 2019 in San Antonio, Texas. If you’re able to attend, be sure to check out our poster, Development of a Library of Plastics Additives for Identification of Extractables. If you can’t make it to the show, we’ve got you covered. Additional Resources The FDA…
Read More →
Development and Validation of In Vitro Release Test (IVRT) Method for Ophthalmic Suspensions Poster Presentation
Nov 4 2019
Avomeen’s pharmaceutical formulation team are attending AAPS PharmSci360 November 3-6, 2019 in San Antonio, Texas. If you’re able to attend, be sure to check out our poster, Development and Validation of In Vitro Release Test (IVRT) Method for Ophthalmic Suspensions – A Walkthrough Exercising Regulatory Guidance. If you can’t make it to the show, we’ve got…
Read More →
Supporting Animal Rescue Organizations is Totally Pawsome
Nov 1 2019
We believe our community deserves our involvement, and in 2019, our team has come together to support local animal rescue organizations. 2019 Doggie Dash Avomeen employees came together along with their 4-legged best friends to support Michigan Humane Society on October 5 at the 2019 Michigan Humane Society Doggie Dash. The Avomeen team, “Totally Pawsome”,…
Read More →
The Key to Successful New Product Development & Innovation
Oct 22 2019
Innovative thinking and ideas often are found though expertise, experimentation, and fresh perspective. At Avomeen, we foster an environment that allows our team to be innovative. Our unique team build allows us to delve into a wide range of formulation needs, ranging from the complex to everyday essentials. Our ability to design proven models for…
Read More →
Pharma Formulation Services Blog Series, Part 4: Wraparound Activities – Measuring Success
Oct 8 2019
Behind every good formulator is… well, are… a number of good analytical chemists. They play a critical role in everything from measuring solubility, potency, and dissolution to monitoring purity and stability. Every step in the formulation development process requires some sort of analysis. Enter, the analytical chemists. Below, we discuss some of the techniques and…
Read More →
New FDA Statement on Impurities in Drug Products
Oct 1 2019
FDA published a statement on September 13, 2019 concerning a nitrosamine impurity in some ranitidine (brand name Zantac) medicines. The impurity is called N-nitrosodimethylamine (NDMA). The FDA has been investigating NDMA in certain heart medications, Angiotensin II Receptor Blockers (ARB’s), since 2018. In June 2018, US manufacturer Prinston Laboratories Inc. contacted FDA about its valsartan-containing…
Read More →
FDA Issues Proposed Rule for ENDS PMTA Pathway
Sep 27 2019
On September 20, 2019, FDA issued a proposed rule which will clearly define requirements for the regulatory pathway for Premarket Tobacco Applications (PMTA). The rule will: Detail content requirements Establish the format for PMTA submissions Specify electronic submission requirements Detail requirements for filing amendments, withdrawal of applications, changes in ownership, and post-market reporting Set requirements…
Read More →